Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.72 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.51 |
| ▸ | UBE2M | P61081 | 1/20 | 0.51 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750908 | 0.97 | RAB9A (0.76) | RAB9AHTTNPC1EPHX1PKM | |
| SCHEMBL21750960 | 0.96 | RAB9A (0.74) | RAB9AHTTNPC1EPHX1PKM | |
| SCHEMBL1322743 | 0.94 | HTT (0.71) | RAB9AHTTNPC1EPHX1PKM | |
| SCHEMBL29419622 | 0.94 | HTT (0.71) | RAB9AHTTNPC1EPHX1PKM | |
| SCHEMBL21750977 | 0.85 | RAB9A (0.72) | RAB9AHTTNPC1EPHX1PKM | |
| SCHEMBL2751089 | 0.84 | RAB9A (1.00) | RAB9AHTTNPC1EPHX1SMN1; SMN2 | |
| SCHEMBL21751023 | 0.82 | RAB9A (0.76) | RAB9AHTTNPC1EPHX1PKM | |
| SCHEMBL29535236 | 0.81 | HTT (0.58) | RAB9AHTTNPC1EPHX1PKM | |
| SCHEMBL21750958 | 0.81 | RAB9A (0.74) | RAB9AHTTNPC1EPHX1SMN1; SMN2 | |
| SCHEMBL28895412 | 0.81 | HTT (0.54) | RAB9AHTTNPC1S1PR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-04-20 | — | — | US | disclosed |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-04-20 | — | — | US | disclosed |
| CN-108530455-B | Urea substituted aromatic ring connecting dioxane and quinazoline compound or medicinal salt or hydrate and application as tyrosine kinase inhibitor | 北京赛特明强医药科技有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BRAF, RAF1, ARAF | RAB9A 2021/4885HTT 3560/4885NPC1 3865/4885 |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BRAF, RAF1, ARAF | RAB9A 2021/4885HTT 3560/4885NPC1 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.